Clinical impact of influenza vaccination after ST- and non-ST-segment elevation myocardial infarction- from the IAMI trial

• Authors: FROEBERT Ole; GOETBERG Matthias; ERLINGE David; AKHTAR Zubair; CHRISTIANSEN Evald H; MACINTYRE Chandini R; OLDROYD Keith G; MOTOVSKA Zuzana; ERGLIS Andrejs; MOER Rasmus; HLINOMAZ Ota; JAKOBSEN Lars; ENGSTROM Thomas; JENSEN Lisette O; FALLESEN Christian O; JENSEN Svend E; ANGERAS Oskar; CALAIS Fredrik; KAREGREN Amra; LAUERMANN Joerg; MOKHTARI Arash; NILSSON Johan; PERSSON Jonas; STALBY Per; ISLAM Abu K M M; RAHMAN Afzalur; MALIK Fazila; CHOUDHURY Sohel; COLLIER Timothy; POCOCK Stuart J; PERNOW John
• Year of publication: 2023
• Type: Article in Periodical
• Magazine / Source: American Heart Journal
• MU Faculty or unit: Faculty of Medicine
• Web: https://www.sciencedirect.com/science/article/pii/S0002870322001983?via%3Dihub
• Doi: http://dx.doi.org/10.1016/j.ahj.2022.10.005
• Keywords: influenza vaccination; myocardial infarction
• Description: Background Influenza vaccination early after myocardial infarction (MI) improves prognosis but vaccine effectiveness may differ dependent on type of MI. Methods A total of 2,571 participants were prospectively enrolled in the Influenza vaccination after myocardial infarction (IAMI) trial and randomly assigned to receive in-hospital inactivated influenza vaccine or saline placebo. The trial was conducted at 30 centers in eight countries from October 1, 2016 to March 1, 2020. Here we report vaccine effective-ness in the 2,467 participants with ST-segment elevation MI (STEMI, n = 1,348) or non-ST-segment elevation MI (NSTEMI, n = 1,119). The primary endpoint was the composite of all-cause death, MI, or stent thrombosis at 12 months. Cumulative incidence of the primary and key secondary endpoints by randomized treatment and NSTEMI/STEMI was estimated using the Kaplan-Meier method. Treatment effects were evaluated with formal interaction testing to assess for effect modification. Results Baseline risk was higher in participants with NSTEMI. In the NSTEMI group the primary endpoint occurred in 6.5% of participants assigned to influenza vaccine and 10.5% assigned to placebo (hazard ratio [HR], 0.60; 95% CI, 0.39-0.91), compared to 4.1% assigned to influenza vaccine and 4.5% assigned to placebo in the STEMI group (HR, 0.90; 95% CI, 0.54-1.50, P = .237 for interaction). Similar findings were seen for the key secondary endpoints of all-cause death and cardiovascular death. The Kaplan-Meier risk difference in all-cause death at one year was more pronounced in participants with NSTEMI (NSTEMI: HR, 0.47; 95% CI 0.28-0.80, STEMI: HR, 0.86; 95% CI, 0.43-1.70, interaction P = .028). Conclusions The beneficial effect of influenza vaccination on adverse cardiovascular events may be enhanced in patients with NSTEMI compared to those with STEMI.